1) The pandemic has had the following impact on the Company's operations: • The Company's sales team has not had direct access to doctors; • The medical system is overwhelmed with pandemic related challenges; and • The public is not focused on chronic disease management, due to the uncertainty associated with the pandemic.
2) PRS on Type 2 diabetes test launch planned The Company is finalising verification of the diabetes test in its Australian laboratory. The Company has completed its marketing collateral, and plan to launch once more normal conditions return post COVID-19.
3) These new COVID-19 related activities may provide some revenue opportunities for the Company in the short term and will assist in the development of additional tests the company is currently working on. The Company has not made significant progress to date that would lead to orders or requests to increase capacity and there is no guarantee the Company will ever receive orders or requests.
Nothing to see here... I thought they would continue to roll out the Type 2 diabetes test, but not with what they have said above..? .
GTG Price at posting:
1.0¢ Sentiment: None Disclosure: Held
